The bisphosphonate zoledronic acid decreases tumor growth in bone in mice with defective osteoclasts. - Test2 - elhamkhani - TriplyDB

The bisphosphonate zoledronic acid decreases tumor growth in bone in mice with defective osteoclasts.

The bisphosphonate zoledronic acid decreases tumor growth in bone in mice with defective osteoclasts.

http://www.wikidata.org/entity/Q39851518

about

Zoledronic acid effectiveness against breast cancer metastases - a role for estrogen in the microenvironment?The ARF tumor suppressor regulates bone remodeling and osteosarcoma development in mice.How do bisphosphonates inhibit bone metastasis in vivo?Modifying the osteoblastic niche with zoledronic acid in vivo-potential implications for breast cancer bone metastasis Updates on osteonecrosis of the jaw Zoledronate inhibits ischemia-induced neovascularization by impairing the mobilization and function of endothelial progenitor cells Integrins and bone metastasis: integrating tumor cell and stromal cell interactions.Anti-tumour activity of bisphosphonates in preclinical models of breast cancer.Effect of zoledronate on oral wound healing in rats.CD8+ T cells regulate bone tumor burden independent of osteoclast resorption.Role of NF-κB in the skeleton Dual-therapy with αvβ3-targeted Sn2 lipase-labile fumagillin-prodrug nanoparticles and zoledronic acid in the Vx2 rabbit tumor model.Breast cancer cell targeting by prenylation inhibitors elucidated in living animals with a bioluminescence reporter.Zoledronic acid in metastatic osteosarcoma: encouraging progression free survival in four consecutive patients Cancer to bone: a fatal attraction.Emerging therapeutic targets in breast cancer bone metastasis.Anticancer properties of zoledronic acid.The critical role of bisphosphonates to target bone cancer metastasis: an overview.Improved union and bone strength in a mouse model of NF1 pseudarthrosis treated with recombinant human bone morphogenetic protein-2 and zoledronic acid.Combined Use of Zoledronic Acid Augments Ursolic Acid-Induced Apoptosis in Human Osteosarcoma Cells through Enhanced Oxidative Stress and Autophagy.Significance of combination therapy of zoledronic acid and gemcitabine on pancreatic cancer.HTLV-1 viral oncogene HBZ induces osteolytic bone disease in transgenic mice.A mathematical model for describing the metastasis of cancer in bone tissue.

P2860

Q33739204-A43E5F45-34C1-4A67-9E0D-037911FB3129 Q33786905-CF4F0F3D-7831-418B-A5E5-6972B539C6B8 Q34009853-BD9183ED-3005-42AB-8801-B5C3FB7E7D6C Q34024176-CC3E7E80-75A5-4D56-B818-DD877458A85A Q34234108-39FDAC18-9E74-444C-8614-B0E5E4897F78 Q34358196-2ACA8947-971C-4187-9291-969338261165 Q34441622-C3F1DF93-6883-474E-A060-5531FFC11ADB Q34613492-4B273D37-2805-4808-95EC-5D9F0C124B73 Q34694368-3EBF0529-1824-468C-82E6-2E5C15F6D938 Q35112793-494A5E79-946B-42CA-AA25-0E420D9E162B Q35347883-DD84A28C-A444-460C-B0A0-338A63E80030 Q36505441-9877F954-5921-4DBF-BB64-98E753E4BC41 Q36708774-FE219441-946B-4927-9AE8-DD0CC894CD17 Q36846801-0EB8388E-A730-42AA-9D3B-84F1F393CED2 Q36884628-6E59EA9D-39F6-414B-A755-83AA5893A81B Q37658767-894EA4AB-A6A8-40D2-9140-122FFA1ED7EA Q37794160-92DEA984-88A5-4C76-8E33-20EE3E9FDFAC Q38247428-90BB88B9-EFFC-40BA-B782-DD71869A3E90 Q38647026-5D8ABE08-C12A-4ADE-966D-A94519C9ABAE Q38727632-BD0F4FCF-97E4-4145-83F2-5E8C79FEBCE8 Q39466674-2C65685A-44E1-4185-BBA4-19B6C8CAE3C8 Q42378329-6D47658B-1D15-403E-BB35-5B1B6D7C7B48 Q51609969-B76FF6D4-0D40-43E1-8F42-4424A1E43FD8

P2860

The bisphosphonate zoledronic acid decreases tumor growth in bone in mice with defective osteoclasts.

http://www.wikidata.org/entity/Q39851518

description

2009 nî lūn-bûn

@nan

2009年の論文

@ja

2009年学术文章

@wuu

2009年学术文章

@zh-cn

2009年学术文章

@zh-hans

2009年学术文章

@zh-my

2009年学术文章

@zh-sg

2009年學術文章

@yue

2009年學術文章

@zh

2009年學術文章

@zh-hant

name

The bisphosphonate zoledronic ...... ce with defective osteoclasts.

@en

The bisphosphonate zoledronic ...... ce with defective osteoclasts.

@nl

type

label

The bisphosphonate zoledronic ...... ce with defective osteoclasts.

@en

The bisphosphonate zoledronic ...... ce with defective osteoclasts.

@nl

prefLabel

The bisphosphonate zoledronic ...... ce with defective osteoclasts.

@en

The bisphosphonate zoledronic ...... ce with defective osteoclasts.

@nl

P1433

Q39851518-3EDEC43E-F929-4060-8B59-87660818361E

P1476

Q39851518-6B88DB1D-DE0F-4545-B317-847E20D32ED7

P2093

Q39851518-133C79D1-21AB-4E62-912C-ECC78D576044

Q39851518-1CAAFD16-BB58-488B-80DF-AF20E312C2B4

Q39851518-26097BB6-CF5E-4DC1-A05E-A15F338F3AD7

Q39851518-578D968F-8907-41C4-8FC6-BB4D1003E751

Q39851518-63A4913B-C51C-42AC-B960-B0A40619C022

Q39851518-A2F034F3-0BD1-4203-ADBB-C7C151F6E81F

Q39851518-A680869D-A441-4866-A1B3-C8A0DB835A97

Q39851518-BA058C75-75F6-4EB8-A445-554B0FFAE9B8

Q39851518-DABE4C8D-FFE4-4F10-9259-B5BD2F7A77A1

Q39851518-DAEF45A1-BD4A-4801-A8C2-F6566D39C93F

P2860

Q39851518-00B1565E-3C6A-412B-9D7B-B918CBD7BD6C

Q39851518-05FAD85C-FB5E-40F3-95F4-A4554F8467AE

Q39851518-09CBA425-CB57-4E37-9CCA-81E3D32B3FFF

Q39851518-0D7D4F7C-BEBC-4523-95A7-463AD387B96F

Q39851518-11289DF9-339C-4EF4-9316-3132A5F31BD8

Q39851518-13CE211E-44AF-4DE5-8BF2-F88363A59BE0

Q39851518-20441A4E-1891-4BF4-8EFC-B660F7FC6050

Q39851518-224749B3-DB36-4152-B204-283FCA9078B8

Q39851518-284C8002-7C7A-4D6E-B82B-65A5CE9A4785

Q39851518-2E249ACE-10DE-48CF-B4EE-1FEED59C8335

P304

Q39851518-09BD8677-F18A-47D1-9FA8-F55451E7CEC1

P31

Q39851518-7C32F39F-6A51-4C73-8A60-EC10E5FAC87A

P356

Q39851518-6D74F0C2-9A58-45BB-8F51-B4E94FA7F9C5

P433

Q39851518-81EBC364-A628-4D68-AC2D-E1EFF7496E0D

P478

Q39851518-89953D52-7019-4052-B54B-AFF60A65AE5A

P50

Q39851518-44B1CF8E-6258-42A1-AA7D-E355DBF853C2

P577

Q39851518-4485B227-6AAF-4675-ADF1-CF1B265979B5

P5875

Q39851518-A25B67DF-C175-4BC1-B47F-37C15DEF4D0F

P698

Q39851518-08F88447-8DEA-4868-94FF-CA9E70DC19F6

P932

Q39851518-1351D992-3D9E-47BD-BC30-6946BCF0AEE5

P356

J.BONE.2009.01.010

P1433

P1476

The bisphosphonate zoledronic ...... ce with defective osteoclasts.

@en

P2093

Angela C Hirbe

http://www.w3.org/2001/XMLSchema#string

Anke J Roelofs

http://www.w3.org/2001/XMLSchema#string

Anthony J Apicelli

http://www.w3.org/2001/XMLSchema#string

David Piwnica-Worms

http://www.w3.org/2001/XMLSchema#string

Desiree H Floyd

http://www.w3.org/2001/XMLSchema#string

Hongju Deng

http://www.w3.org/2001/XMLSchema#string

Julie L Prior

http://www.w3.org/2001/XMLSchema#string

Katherine Weilbaecher

http://www.w3.org/2001/XMLSchema#string

Lisa G Lanigan

http://www.w3.org/2001/XMLSchema#string

Mark C Eagleton

http://www.w3.org/2001/XMLSchema#string

P2860

Granulocyte colony-stimulating factor enhances bone tumor growth in mice in an osteoclast-dependent manner

Impaired recruitment of bone-marrow-derived endothelial and hematopoietic precursor cells blocks tumor angiogenesis and growth

Alendronate is a specific, nanomolar inhibitor of farnesyl diphosphate synthase

Src kinase activity is essential for osteoclast function

Targeted disruption of the c-src proto-oncogene leads to osteopetrosis in mice

Metastasis to bone: causes, consequences and therapeutic opportunities

Bone histomorphometry: standardization of nomenclature, symbols, and units. Report of the ASBMR Histomorphometry Nomenclature Committee

Structure-activity relationships for inhibition of farnesyl diphosphate synthase in vitro and inhibition of bone resorption in vivo by nitrogen-containing bisphosphonates.

Tumor-derived interleukin-8 stimulates osteolysis independent of the receptor activator of nuclear factor-kappaB ligand pathway.

Platelet and osteoclast beta3 integrins are critical for bone metastasis.

P304

908-916

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.BONE.2009.01.010

http://www.w3.org/2001/XMLSchema#string

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

44

http://www.w3.org/2001/XMLSchema#string

P50

Michael J. Rogers

P577

2009-01-23T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

24427701

http://www.w3.org/2001/XMLSchema#string

P698

19442620

http://www.w3.org/2001/XMLSchema#string

P932

2782613

http://www.w3.org/2001/XMLSchema#string